Who’s Who: The Healthcare Ecosystem
By DeltaMV Insights TeamReviewed by DeltaMV Academy EditorialUpdated 6 min read
Module 1 · 9 of 10Foundations of Healthcare Market ResearchAll articles
- What Is Market Research, Really? A Beginner’s Map of the Field
- Why Healthcare Market Research Is Different From Consumer Research
- A Short History: How Pharma & Healthcare Market Research Evolved
- Ethics, Compliance & Data Privacy in Healthcare Market Research
- Types of Healthcare Market Research Studies: Trackers, Ad Hoc, Syndicated & Custom
- How a Market Research Project Actually Runs
- Qualitative vs Quantitative Research
- Primary vs Secondary Research
- Who’s Who: The Healthcare Ecosystem
- Common Myths About Market Research
Healthcare treatment decisions involve a shifting cast of players: pharma companies, payers, providers, and patients, each with different incentives and different amounts of influence depending on the market and decision. Understanding who’s who in this ecosystem is the first step before any stakeholder mapping or influence analysis, covered later in this Academy.
Key Takeaways
- Healthcare isn’t a two-party market of seller and buyer. It typically involves at least four distinct groups, pharma and manufacturers, payers, providers, and patients, each with different goals.
- “Payer” and “provider” are often confused. Payers fund or reimburse care. Providers deliver it.
- The relative influence of each group shifts significantly by market, by disease category, and by how care is funded locally.
- This article is a general map of who’s in the ecosystem. The specific technique for mapping influence on a single treatment decision is covered later in Module 4.
- Getting the ecosystem map wrong at the start is one of the most common reasons healthcare research ends up targeting the wrong respondents.
The Problem With Thinking There’s Just One “Customer”
Teams coming from a consumer research background often default to assuming a single decisionmaker, like a shopper choosing between products on a shelf. Healthcare rarely works that way. A single treatment decision can be shaped by a physician’s clinical judgment, a payer’s reimbursement rules, a patient’s preferences and ability to pay, and sometimes a caregiver’s practical concerns, all at once. Treating any one of these as the sole “customer” is one of the fastest ways to design research that answers the wrong question.
The Four Main Players
- Pharma and manufacturers develop and market treatments. Commercial success is tied to clinical outcomes and patient access and influence happens through evidence generation, physician engagement, and sometimes patient support programs.
- Payers are the organisations that fund or reimburse treatment, which depending on the market, might be a government health system, a private insurer, or a pharmacy benefit manager. Their goal is managing cost and outcomes across a population which can sometimes conflict with what’s best for one individual patient.
- Providers are physicians, nurses, pharmacists, and the institutions delivering care. Their goal is typically the best outcome for the individual patient in front of them informed by clinical evidence, guidelines, and their own experience.
- Patients and caregivers are the people receiving treatment whose goals include clinical outcomes but also quality of life, cost burden, and convenience. They’re increasingly influential as health systems emphasise patient-centred care and patients access more information independently.
How the Balance of Power Shifts
The balance between these four groups isn’t fixed. It moves depending on context. By market, systems with national health coverage tend to concentrate more decision power with payers and government bodies, while markets with more private insurance or out-of-pocket payment shift more power toward providers and patients. By disease category, rare or highly specialised conditions can concentrate decision power with a small number of expert providers, while common chronic conditions are often shaped more by broad payer formularies and patient preference. By stage of the patient journey, providers tend to dominate early in diagnosis, while patient adherence and preference matter more later, especially for long-term or self-managed conditions.
Practical Implications for Research Design
None of this is abstract once you’re scoping a project. Before finalising a respondent list, it’s worth asking which of the four groups actually controls the decision being studied, rather than defaulting to whichever group is easiest to recruit or most familiar from past projects. A study built only around physicians will miss a payer-driven access barrier. A study built only around patients will miss a provider’s clinical hesitation that never reaches the patient at all. In practice, this often means budgeting for more than one audience even when a brief initially names only one, and being explicit with stakeholders early about why the respondent mix looks the way it does, since it’s rarely obvious from the outside why a payer-perspective interview matters for what looks like a physician-messaging question.
What’s Still Genuinely Uncertain
The rising influence of patients, through advocacy groups, online communities, and direct access to information, is reshaping the traditional balance, but exactly how much weight patient preference carries relative to provider and payer decisions still varies enormously and resists easy generalisation across markets. Digital health tools and AI-assisted diagnosis support are also starting to introduce new quasi-stakeholders into the picture, and their influence on the traditional four-party balance isn’t fully mapped out yet.
The Cheat Sheet
Four main players with four different goals: pharma wants adoption and evidence, payers want managed cost across a population, providers want the best outcome for the patient in front of them, and patients want positive outcomes that are affordable and ensure quality of life. Most healthcare decisions are a negotiation between all four rather than a decision made by just one.
A DeltaMV Perspective
On an early scoping call for a new market entry, the initial respondent list focused almost entirely on specialists, treating them as the sole decisionmaker for a chronic condition. A short desk review of how the condition was actually funded in that market revealed a national reimbursement body with substantial influence over which treatments were even accessible, regardless of specialist preference. The research design shifted to include a payer-perspective component alongside the physician interviews, even though no one on the client side had originally flagged payers as a priority audience. Without that addition, the study would have produced a confident, well-supported answer to the wrong question: what physicians preferred, not what patients could actually access. The ecosystem map must be checked against the specific market and decision at hand, not assumed from experience in a different one.
Composite/anonymized example; not a specific client or study.
FAQ
What’s the difference between a payer and a provider?
A payer funds or reimburses healthcare, such as a government health system, private insurer, or pharmacy benefit manager. A provider delivers care directly, such as a physician, nurse, pharmacist, or hospital. They’re often confused because both sit between the manufacturer and the patient, but their roles and incentives are distinct.
Are patients becoming more influential in treatment decisions?
In many markets, yes. Patient advocacy groups, online health communities, and greater access to information have increased patient influence, particularly for conditions involving long-term self-management, but the degree varies significantly by market and condition.
Does every healthcare decision involve all four stakeholder groups?
Not equally. Depending on the market and the condition, one or two groups often dominate, for example a national payer in a public health system, or a specialist for a rare condition with few treatment options, but it’s worth checking rather than assuming.
How is this different from stakeholder mapping covered elsewhere in this Academy?
This article is a general overview of who the major players are in healthcare. Stakeholder mapping, covered later in Module 4, is the specific technique for identifying and weighting which stakeholders matter most for one particular treatment decision.
The Bottom Line
Healthcare decisions are rarely made by a single player. They’re negotiated across pharma, payers, providers, and patients, each with different goals and different amounts of influence depending on the market, condition, and stage of the journey. Getting this map right before designing any research is what keeps a study pointed at the people who actually shape the decision.